- Home
- ROIV vs CQP Comparison
ROIV vs CQP Comparison
Compare ROIV & CQP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROIV | CQP |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil/Gas Transmission |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 32.3B |
| IPO Year | 2021 | 2006 |
Fundamental Metrics
Financial Performance| Metric | ROIV | CQP |
|---|---|---|
| Price | $36.89 | $67.05 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 13 | 14 |
| Target Price | $50.00 | ★ $60.08 |
| AVG Volume (30 Days) | ★ 6.2M | 68.8K |
| Earning Date | 11-09-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 4.89% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | $8,260,000.00 | ★ $10,758,000,000.00 |
| Revenue This Year | $593.33 | $4.62 |
| Revenue Next Year | $648.48 | N/A |
| P/E Ratio | ★ N/A | $966.43 |
| Revenue Growth | N/A | ★ 23.60 |
| 52 Week Low | $19.30 | $49.76 |
| 52 Week High | $42.50 | $71.25 |
Technical Indicators
Market Signals| Indicator | ROIV | CQP |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 59.60 |
| Support Level | $33.11 | $62.24 |
| Resistance Level | $37.89 | $70.07 |
| Average True Range (ATR) | 1.25 | 1.72 |
| MACD | 0.32 | 0.45 |
| Stochastic Oscillator | 70.31 | 86.54 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CQP Cheniere Energy Partners LP
Cheniere Energy Partners is a liquefied natural gas producer operating one facility in Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed- and variable-fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. The profit generated through those activities is split with parent and operator Cheniere Energy.